Active, not recruitingPhase 2NCT03779711

Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Repair of Hypoplastic Left Heart Syndrome

Studying Hypoplastic left heart syndrome

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Timothy J Nelson, MD, PhD
Principal Investigator: Frank Cetta, MD
Mayo Clinic
Intervention: Autologous (self) mononuclear cells derived from umbilical cord blood(biological)
Enrollment: 95 enrolled
Eligibility: All sexes
Timeline: 2019 – 2026

Study locations (8)

Children's of Alabama, Birmingham, Alabama, United States
Children's Hospital of Los Angeles, Los Angeles, California, United States
Children's Hospital Colorado, Aurora, Colorado, United States
Ocshner Medical Center, New Orleans, Louisiana, United States
Children's Hospitals of Minnesota, Minneapolis, Minnesota, United States
Cincinnati Children's Hospital and Medical Center, Cincinnati, Ohio, United States
Oklahoma University Medical Center, Oklahoma City, Oklahoma, United States
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

Collaborators

University of Oklahoma · Children's Hospital of Philadelphia · Children's Hospital Los Angeles · Children's Hospital Colorado · Children's Hospitals and Clinics of Minnesota · Ochsner Health System · Children's of Alabama · Children's Hospital Medical Center, Cincinnati

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03779711 on ClinicalTrials.gov

Other trials for Hypoplastic left heart syndrome

Additional recruiting or active studies for the same condition.

See all trials for Hypoplastic left heart syndrome →

← Back to all trials